Project Details
Description
A Phase 2 Efficacy and Safety, Open-label, Multicenter Study of Imprime PGG Injection in Combination with Cetuximab (Erbitux) in Subjects with Stage IV KRAS-Mutated Colorectal Cancer
| Status | Finished |
|---|---|
| Effective start/end date | 1/1/08 → 3/30/11 |
Funding
- BIOTHERA
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.